A retrospective study of the BiRd regimen in the treatment of relapsed/ refractory multiple myeloma
10.3760/cma.j.issn.0253-2727.2017.10.003
- VernacularTitle: BiRd方案治疗复发难治多发性骨髓瘤的回顾性研究
- Author:
Xuelian LIU
1
;
Lu LI
;
Qinglin SHI
;
Lijuan CHEN
;
Xinxin CAO
;
Jian LI
;
Aijun LIAO
;
Dehui ZOU
;
Jingnan SUN
;
Sujun GAO
;
Wei LI
;
Jian HOU
;
Fengyan JIN
Author Information
1. Cancer Center, the First Hospital of Jilin University, Changchun 130012, China
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Clarithromycin;
Retrospective studies;
Treatment outcome;
Survival analysis
- From:
Chinese Journal of Hematology
2017;38(10):837-841
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate efficacy of the BiRd regimen, a combination of clarithromycin, lenalidomide, and dexamethasone, in the treatment of patients with relapsed/refractory multiple myeloma (RRMM) .
Methods:Patients with RRMM treated with BiRd between September 11, 2013 and August 1, 2016 at six centers were included to evaluate overall survival rate (ORR) , clinical benefit rate (CBR) , progression-free survival (PFS) , overall survival (OS) , as well as adverse events.
Results:Of 30 patients with RRMM, 27 patients were evaluable, and ORR and CBR were 51.9% (14/27) and 66.7% (18/27) respectively, including 1 sCR (3.7%) , 3 CR (11.1%) , 3 VGPR (11.1%) , and 7 PR (25.6%) . In 13 patients with prior Rd, ORR and CBR were 38.5% (5/13) and 61.5% (8/13) respectively, of which 5 patients with ≥MR carried high-risk cytogenetic[ (e.g.17p- or t (4;14) ] together with at least one of other adverse-prognostic cytogenetic (e.g.13q- and/or 1q21+) . In 24 patients with prior bortezomib-based therapy, ORR and CBR were 45.8 and 62.5%, respectively. With a median follow-up time of 14.9 (range 1.0-33.8) months, the median PFS and OS were 12.0 (95%CI 11.6-12.4) and 27.6 (95%CI 15.1-40.1) months, respectively. The BiRd regimen was well tolerated.
Conclusion:The BiRd regimen is an effective and safety protocol for RRMM, including those carrying high-risk cytogenetic markers.
